Jump to content

GlobalSurg-3 study


Recommended Posts

Dear all,
The GlobalSurg Collaborative is an international research network that 
focuses on improving surgical care in low- and middle-income countries. 
A total of 343 centres across 66 countries participated in GlobalSurg's 
most recent study, which focused on surgical site infection. This was 
published in Lancet Infectious Disease (impact factor 17) last month 
gathering widespread media attention, including the Telegraph front 
page, Times, Daily Mail, and BBC News. GlobalSurg has a corporate 
authorship policy, with all collaborators listed as PubMed-citable 
The next study focuses on quality of breast, colon, and gastric cancer 
surgery. It is designed to be relevant to both high and low resource 
settings, so participation from NHS units is encouraged. Teams of up to 
three individuals will collect data over 4 consecutive weeks on all 
patients undergoing surgery for breast, colon, and gastric cancer (in 
very busy centres you may collect just breast or GI cases). Each patient 
should be followed-up for 30 days. The window for data collection runs 
from 1 April 2018 - 31 October 2018. Multiple teams may participate at 
each centre collecting data over distinct 4 week periods within the data 
collection window.
The full protocol will shortly be published online at 
To get involved, please enter your details on our online google sheet 
and link up with anyone else already interested at your site: 
If you have friends and colleagues abroad (particularly in low- and 
middle- income countries) who might be interested in participating, 
please do share this opportunity with them, or forward my email 
(d.nepogodiev@bham.ac.uk) contact to them.
Please do not hesitate to get in touch if you have any questions about 
the project.
Best wishes,
On behalf of the GlobalSurg Collaborative

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.